Covestro Pharmaceuticals (688136.SH) released its half year financial results, with a net profit attributable to the parent company of 80.3445 million yuan, an increase of 576.45% year-on-year.

Zhixin Financial APP News, Kexing Pharmaceuticals (688136.SH) released its 2025 interim report. During the reporting period, the company achieved operating income of 700 million yuan, a year-on-year decrease of 7.82%. The net profit attributable to the shareholders of the listed company was 80.3445 million yuan, a year-on-year increase of 576.45%. The net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 45.2791 million yuan, a year-on-year increase of 110.30%. Basic earnings per share were 0.41 yuan.